Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 3/2013

01-09-2013 | Risk, Prevention, and Screening (DL Hershman, Section Editor)

Aspirin and Breast Cancer Prevention

Authors: Matteo Lazzeroni, Marilena Petrera, Domenico Marra, Andrea DeCensi

Published in: Current Breast Cancer Reports | Issue 3/2013

Login to get access

Abstract

Over the past decade, breast cancer chemoprevention has made substantial progress, particularly with selective estrogen receptor modulators and aromatase inhibitors. A new generation of chemopreventive agents modulating the non-endocrine biochemical pathways has been studied so far, including the 100-year-old drug aspirin. Commonly known as pain-reliever, aspirin may also influence breast carcinogenesis through a number of mechanisms, including decreased production of prostaglandins, which can inhibit angiogenesis and inhibit apoptosis, inhibition of the cyclo-oxygenase enzymatic pathways and stimulation of the AMPk pathway leading to decreased proliferation and increased autophagy. Long-term follow-up of randomized trials of aspirin in prevention of vascular events showed that daily aspirin reduced the incidence of colorectal cancer and several other cancers, including a borderline effect on breast cancer incidence. In the present review, we discuss the potential role aspirin in breast cancer prevention comparing data from observational studies with those from the randomized trials.
Literature
1.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
2.
Baqai T, Shousha S. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast. Histopathology. 2003;42:440–7.PubMedCrossRef
3.
Provenzano E, Hopper JL, Giles GG, et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer. 2003;39:622–30.PubMedCrossRef
4.
Cazzaniga M, Bonanni B. Prevention of ER-negative breast cancer: where do we stand? Eur J Cancer Prev. 2012;21:171–81.PubMedCrossRef
5.
Subbaramaiah K, Morris PG, Zhou XK, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2012;2:356–65.PubMedCrossRef
6.
Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387–437.PubMedCrossRef
7.
Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6:130–40.PubMedCrossRef
8.
Zhao Y, Agarwal VR, Mendelson CR, et al. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996;137:5739–42.PubMedCrossRef
9.
Brueggemeier RW, Quinn AL, Parrett ML, et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 1999;140:27–35.PubMedCrossRef
10.
Elvin JA, Yan C, Matzuk MM. Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E2/EP2 receptor pathway. Proc Natl Acad Sci U S A. 2000;97:10288–93.PubMedCrossRef
11.
12.
Stark LA, Reid K, Sansom OJ, et al. Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis. 2007;28:968–76.PubMedCrossRef
13.
Yan F, He Q, Hu X, et al. Direct regulation of caspase3 by the transcription factor AP2alpha is involved in aspirininduced apoptosis in MDAMB453 breast cancer cells. Mol Med Rep. 2013;7:909–14.PubMed
14.
Borthwick GM, Johnson AS, Partington M, et al. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J. 2006;20:2009–16.PubMedCrossRef
15.
Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 1804;2010:581–91.
16.
Chen D, Pamu S, Cui Q, et al. Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem. 2012;20:3031–7.PubMedCrossRef
17.
Rattan R, Giri S, Singh AK, et al. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 2005;280:39582–93.PubMedCrossRef
18.
Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507–11.PubMedCrossRef
19.
• Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336:918–22. AMPK activation could explain some beneficial effects of aspirin in humans. PubMedCrossRef
20.
Din FV, Valanciute A, Houde VP, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142:1504–15.PubMedCrossRef
21.
Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291:2433–40.PubMedCrossRef
22.
Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28:1467–72.PubMedCrossRef
23.
Holmes MD, Chen WY, Schnitt SJ, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 2011;130:657–62.PubMedCrossRef
24.
• Zhang X, Smith-Warner SA, Collins LC, et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 2012;30:3468–77. A recent update of the Nurses’ Health Study on breast cancer mortality risk according to number of days per week of aspirin use. PubMedCrossRef
25.
Li Y, Brasky TM, Nie J, et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2012;21:239–42.PubMedCrossRef
26.
27.
Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf. 2008;17:115–24.PubMedCrossRef
28.
Takkouche B, Regueira-Mendez C. Etminan M: breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 2008;100:1439–47.PubMedCrossRef
29.
Zhao YS, Zhu S, Li XW, et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat. 2009;117:141–50.PubMedCrossRef
30.
Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23:1403–15.PubMedCrossRef
31.
Luo T, Yan HM, He P, et al. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2012;131:581–7.PubMedCrossRef
32.
Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294:47–55.PubMedCrossRef
33.
•• Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–601. The most recent study of incident cancers during randomized controlled trials. PubMedCrossRef
34.
Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–27.PubMedCrossRef
35.
Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke. 2005;36:1801–7.PubMedCrossRef
36.
Lee M, Cryer B, Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med. 1994;120:184–9.PubMedCrossRef
37.
Baron JA, Cole BF, Sandler RS, et al. A randomised trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–9.PubMedCrossRef
38.
Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827–30.PubMedCrossRef
39.
Metadata
Title
Aspirin and Breast Cancer Prevention
Authors
Matteo Lazzeroni
Marilena Petrera
Domenico Marra
Andrea DeCensi
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 3/2013
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-013-0115-y

Other articles of this Issue 3/2013

Current Breast Cancer Reports 3/2013 Go to the issue

Risk, Prevention, and Screening (DL Hershman, Section Editor)

Statins and Breast Cancer: Future Directions in Chemoprevention

Risk, Prevention, and Screening (DL Hershman, Section Editor)

Alcohol Intake and Breast Cancer Risk: Weighing the Overall Evidence

Risk, Prevention, and Screening (DL Hershman, Section Editor)

Weight Loss Intervention for Breast Cancer Survivors: A Systematic Review

Risk, Prevention, and Screening (DL Hershman, Section Editor)

Breast Surveillance of Patients with BRCA1 and BRCA2 Mutations

Risk, Prevention, and Screening (DL Hershman, Section Editor)

Biomarker Endpoints for Early-Phase Cancer-Prevention Studies

Risk, Prevention, and Screening (DL Hershman, Section Editor)

Mammographic Density: Potential as a Risk Factor and Surrogate Marker in the Clinical Setting
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits